全体要約
エンドユーザー別では、製薬・バイオテクノロジー企業がコンパニオン診断の主要な利用者です。個別化医療への関心増加と、病気に対する標的療法の必要性が、製薬企業におけるコンパニオン診断の需要を押し上げています。また、アジア太平洋地域は、医療費の増加や早期病発見の啓発活動が進む中で、最も高い成長率を記録すると予測されています。
関連する質問
136億XX米ドル (2029年)
12.6% (2024年から2029年)
F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Abbott, Almac Group, Danaher, Illumina, Inc., bioMérieux, Myriad Genetics, Inc., Sysmex Corporation, ARUP Laboratories, Abnova Corporation, Guardant Health, ICON Plc, BioGenex, Invivoscribe, Inc., ArcherDX, Inc., NG Biotech, Q² Solutions, Amoy Diagnostics Co., Ltd., Uniogen, Asuragen, Inc., Meso Scale Diagnostics, LLC., Creative Biolabs
医薬品開発におけるコンパニオン診断の重要性の高まり, がん発症率の上昇, ターゲット治療の普及
概要
「アッセイ、試薬およびキットのセグメントは、予測期間中に製品とサービス別でコンパニオン診断市場で最も高い成長率を達成すると予想されます。」
コンパニオン診断市場は、製品・サービスに基づいて、アッセイ、キット＆試薬、機器／システム、およびソフトウェア＆サービスに分類されます。2023年には、アッセイ、キット＆試薬セグメントが市場の最大シェアを占めました。これは、利用可能な製品の広範囲、さまざまな治療分野でのアッセイやキットの利用増加、基本研究および商業アプリケーションにおけるこれらの製品の需要増加などの要因に起因しています。
「製薬およびバイオテクノロジー企業セグメントは、予測期間中に最も高いCAGRを占めると予測されています。」
最終ユーザーに基づいて、コンパニオン診断市場は製薬・バイオテクノロジー企業、リファレンスラボ、CRO、その他の最終ユーザーにセグメント化されています。
2023年には、製薬およびバイオテクノロジー企業が市場における主要なコンパニオン診断の利用者として際立っています。この顕著な地位は、主に薬剤開発におけるコンパニオン診断の採用増加と、コンパニオン診断バイオマーカーの重要性の高まりに起因しています。さらに、個別化医療への関心の高まりと、さまざまな疾患や障害におけるターゲット療法のニーズの高まりは、製薬およびバイオテクノロジー企業におけるコンパニオン診断の需要と統合を促進すると予測されています。
「アジア太平洋：コンパニオン診断市場で最も成長が早い地域」
グローバルなコンパニオン診断市場は、北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東＆アフリカ、GCC諸国に分かれています。アジア太平洋地域は、予測期間中に最も高いCAGRを記録することが期待されています。この成長は、医療費の増加、製薬研究資金の増加、早期疾病検出に関する意識を高めるための政府の取り組み、様々なAPAC諸国における私立病院の農村地域への拡大、そして地域内の高成長市場の存在などの要因に起因しています。
このレポートのために行われた主要なインタビューは以下のように分類できます：
• 会社の種類別：ティア1 - 20%、ティア2 - 45%、ティア3 - 35%
• 役職別：Cレベル - 30%、Dレベル - 20%、その他 - 50%
• 地域別：北米 - 42%、ヨーロッパ - 31%、アジア太平洋 - 20%、その他の地域 - 7%
レポートに掲載された企業の一覧：
F. ホフマン・ラ・ロシュ株式会社（スイス）
アジレント・テクノロジーズ株式会社（米国）
・QIAGEN（オランダ）
・サーモフィッシャーサイエンティフィック社（米国）
・アボット（アメリカ）
• アルマックグループ（イギリス）
・ダナハー（米国）
イルミナ社（アメリカ）
バイオメリュー（フランス）
• マイリアド・ジェネティクス社 (アメリカ)
・シスメックス株式会社（日本）
• アラップラボラトリーズ（英国）
アブノバ株式会社 (台湾)
・ガーダント・ヘルス（米国）
• ICON Plc（アイルランド）
バイオジェネックス（米国）
インビボスクライブ社（米国）
・アーチャーDX株式会社（インテグレイテッドDNAテクノロジーズ株式会社）（米国）
NGバイオテック（フランス）
Q²ソリューションズ（米国）
アモイ・ダイアグノスティクス株式会社（中国）
・ユニオジェン（アバカス・ダイアグノスティカ）(フィンランド)
アスラゲン社（バイオテクニカ）（アメリカ）
・NGバイオテクノロジー（フランス）
メゾスケール・ダイアグノスティクス、LLC（アメリカ）
クリエイティブバイオラボ（米国）
研究範囲:
この調査報告書は、コンパニオン診断市場を製品、タイプ、アプリケーション、および地域別にカテゴリ分けしています。報告書の範囲には、コンパニオン診断市場の成長に影響を与える主要な要因、つまりドライバー、制約、課題、および機会に関する詳細情報が含まれています。主要な業界プレーヤーの詳細な分析が行われており、彼らのビジネス概要、ソリューション、主要戦略、契約、パートナーシップ、合意、新製品の発売、合併および買収、およびコンパニオン診断市場に関連する最近の展開についての洞察を提供。コンパニオン診断市場エコシステムにおける新興スタートアップの競争分析もこの報告書で取り上げられています。
報告書を購入する主な利点：
このレポートは、市場のリーダーや新規参入者が全体のコンパニオン診断市場およびそのサブセグメントの収益数値について最も近い推定値を得る手助けをします。また、利害関係者が競争環境をよりよく理解し、自社のビジネスを適切に位置づけ、適切な市場進出戦略を立てるための洞察を得ることにも役立ちます。このレポートは、利害関係者が市場の脈動を理解し、市場の主要なドライバー、制約、課題、および機会に関する情報を提供します。
レポートは以下のポイントに関する洞察を提供します。
伴走診断市場の成長に影響を与える主要なドライバー、制約、機会、課題の分析です。
• 製品開発/イノベーション: 伴走診断市場における今後の技術、研究開発活動、および新製品の発売に関する詳細な洞察です。
市場開発：収益性の高い市場に関する包括的な情報 - この報告書は、さまざまな地域にわたるコンパニオン診断市場を分析しています。
市場の多様化：コンパニオン診断市場における新製品、未開拓の地域、最近の動向、投資に関する詳細情報です。
競争評価：F. ホフマン・ラ・ロシュ社（スイス）、アジレント・テクノロジーズ社（米国）、QIAGEN（オランダ）、テルモ・フィッシャー・サイエンティフィック社（米国）、およびアボット社（米国）などの主要プレーヤーの市場ランキング、成長戦略、製品提供の詳細な評価です。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 イントロダクション 46
1.1 調査の目的 46
1.2 市場の定義 46
1.2.1 包含・除外事項 47
1.3 市場セグメンテーション 48
1.3.1 対象市場 48
1.3.2 対象地域 49
1.3.3 対象年 49
1.4 通貨 50
1.5 調査上の制約 50
1.6 ステークホルダー 50
1.7 変化のサマリー 51
1.7.1 リセッション時のインパクト 51
2 調査手法 52
2.1 リサーチデータ 52
2.2 調査アプローチ 52
2.2.1 二次データ 53
- 2.2.1.1 二次情報の主要データ 54
2.2.2 一次データ 55
- 2.2.2.1 一次情報 55
- 2.2.2.2 一次情報の主要データ 56
- 2.2.2.3 業界についての主な考察 57
- 2.2.2.4 一次インタビュー内訳 57
2.3 市場規模予測 58
2.3.1 ボトムアップアプローチ 59
- 2.3.1.1 アプローチ1：会社の収益推定アプローチ 59
- 2.3.1.2 アプローチ2：企業プレゼンテーションと一次インタビュー 59
- 2.3.1.3 成長予測 60
- 2.3.1.4 CAGR予測 60
2.3.2 トップダウンアプローチ 60
2.4 市場の内訳とデータのトライアンギュレーション 62
2.5 調査の前提 63
2.6 成長率の前提 63
2.7 制約 63
2.8 リスク評価 64
2.8.1 リスク評価分析 64
2.9 リセッション時のインパクト分析 64
3 エグゼクティブサマリー 66
4 更なる考察 71
4.1 コンパニオン診断市場の概要 71
4.2 コンパニオン診断市場シェア、製品・サービス別 <num4>年 vs. <num4>年 71
4.3 コンパニオン診断市場シェア、技術別 <num4>年 vs. <num4>年 72
4.4 コンパニオン診断市場シェア、適応症別 <num4>年 vs. <num4>年 72
4.5 コンパニオン診断市場、サンプルタイプ別シェア、2024年対2029年 73
4.6 コンパニオン診断市場シェア、エンドユーザー別 <num4>年 vs. <num4>年 73
4.7 コンパニオン診断市場、地理的側面での成長機会 74
5 市場概要 75
5.1 イントロダクション 75
5.2 市場ダイナミクス 75
5.2.1 促進要因 76
5.2.2 抑制要因 79
- 5.2.2.1 多額の設備投資と低い費用対効果 79
- 5.2.2.2 コンパニオン診断テストの高コスト 80
- 5.2.2.3 不利な払い戻し 80
- 5.2.2.4 免疫療法の治療費が高い 81
5.2.3 市場機会 82
- 5.2.3.1 次世代シーケンサーの需要拡大 82
- 5.2.3.2 医薬品開発におけるコンパニオン診断の意義が高まる 83
- 5.2.3.3 ゲノム研究の進展と臨床試験の増加 83
5.2.4 課題 84
- 5.2.4.1 医療従事者の不足 84
- 5.2.4.2 新興市場での認知度は限定的 84
5.3 価格分析 85
5.4 特許分析 86
5.5 取引分析・貿易分析 87
5.5.1 診断・検査試薬の貿易分析 87
5.6 バリューチェーン分析 87
5.7 サプライチェーン分析 89
5.8 エコシステム分析 90
5.9 ポーターのファイブフォース分析 91
5.9.1 新規参入の脅威 91
5.9.2 代替品の脅威 91
5.9.3 買い手の交渉力 91
5.9.4 サプライヤーの交渉力 92
5.9.5 競合・競争状況の激しさ 92
5.10 規制の概観 92
5.10.1 規制当局、政府機関、その他組織 92
5.10.2 北米 94
- 5.10.2.1 米国 94
- 5.10.2.2 カナダ 94
5.10.3 ヨーロッパ 94
5.10.4 アジア太平洋 95
- 5.10.4.1 中国 95
- 5.10.4.2 日本 95
- 5.10.4.3 インド 96
5.10.5 ラテンアメリカ 96
- 5.10.5.1 ブラジル 96
- 5.10.5.2 メキシコ 97
5.10.6 中東 97
5.10.7 アフリカ 97
5.11 技術分析 97
5.11.1 キーテクノロジー 98
- 5.11.1.1 ポリメラーゼ連鎖反応（PCR） 98
- 5.11.1.2 次世代シーケンス（NGS） 98
5.11.2 コンプリメンタリー・テクノロジー 98
- 5.11.2.1 In situ ハイブリダイゼーション（ISH） 98
5.11.3 アディショナルテクノロジー 98
- 5.11.3.1 免疫組織化学（IHC） 98
5.12 2024-2025年の主な会議とイベント 99
5.13 顧客事業にインパクトのあるトレンド/ディスラプション 100
5.13.1 コンパニオン診断市場の収益ポケット 100
5.14 主なステークホルダーと購入基準 101
5.14.1 購買プロセスにおける主要ステークホルダー 101
5.14.2 購買基準 102
5.15 投資と資金調達のシナリオ 103
6 コンパニオン診断市場、製品・サービス別 104
6.1 イントロダクション 105
6.2 アッセイ、キット、試薬 105
6.3 機器・システム 109
6.3.1 市場成長を確実にするNGS技術の最新進歩 109
6.4 ソフトウェア・サービス 112
7 コンパニオン診断の市場、技術別 116
7.1 イントロダクション 117
7.2 ポリメラーゼ連鎖反応 117
7.3 In Situハイブリダイゼーション 121
7.3.1 小腫瘍診断の需要増加が成長を牽引 121
7.4 次世代シーケンサー 124
7.5 免疫組織化学 128
7.5.1 ユーザーフレンドリーで費用対効果の高い技術への需要の高まりが成長を支える 128
7.6 その他の技術 131
8 コンパニオン診断の市場、インディケーション別 135
8.1 イントロダクション 136
8.2 がん 136
8.2.1 肺がん 139
- 8.2.1.1 効果的な治療薬への需要の高まりがCDxの採用を増加させる 139
8.2.2 乳がん 143
- 8.2.2.1 乳がんの蔓延が市場成長を押し上げる 143
8.2.3 血液がん 146
- 8.2.3.1 血液がんの罹患率の増加が市場を牽引 146
8.2.4 大腸がん 149
8.2.5 その他のがん 152
8.3 神経系疾患 154
8.4 循環器系疾患 157
8.4.1 標的治療への需要の高まりが同分野の成長を牽引 157
8.5 感染症 160
8.5.1 標的治療に対する意識の高まりが成長を促進 160
8.6 その他の適応症 163
9 コンパニオン診断の市場、サンプルタイプ別 166
9.1 イントロダクション 167
9.2 組織サンプル 167
9.2.1 包括的なプロファイリングと高感度が市場を牽引 167
9.3 血液サンプル 170
9.3.1 より侵襲の少ない方法-採用を促進する重要な要因 170
9.4 その他のサンプル 173
10 コンパニオン診断の市場、エンドユーザー別 177
10.1 イントロダクション 178
10.2 製薬会社・バイオテクノロジー企業 178
10.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET 178
10.3 レファレンス・ラボラトリーズ 181
10.3.1 標的治療薬に対する需要の高まりが成長を促進 181
10.4 受託研究機関 184
10.5 その他のエンドユーザー 187
11 コンパニオン診断の市場、地域別 191
11.1 イントロダクション 192
11.2 北米 192
11.2.1 北米：リセッション時のインパクト 197
11.2.2 米国 198
11.2.3 カナダ 201
- 11.2.3.1 政府のイニシアティブの高まりが市場を牽引 201
11.3 ヨーロッパ 205
11.3.1 ヨーロッパ：リセッション時のインパクト 209
11.3.2 ドイツ 210
- 11.3.2.1 医療費の増加が市場を牽引 210
11.3.3 英国 213
11.3.4 スイス 217
- 11.3.4.1 市場成長を支える強力な研究志向の製薬業界 217
11.3.5 フランス 220
- 11.3.5.1 市場成長を支える政府研究費の増加 220
11.3.6 イタリア 224
- 11.3.6.1 高齢者人口の増加が市場を牽引 224
11.3.7 スペイン 227
11.3.8 その他のヨーロッパ 231
11.4 アジア太平洋 235
11.4.1 アジア太平洋：リセッション時のインパクト 240
11.4.2 中国 240
- 11.4.2.1 医療施設の進歩が市場を牽引 240
11.4.3 日本 244
- 11.4.3.1 市場成長を支える研究イニシアティブの増加 244
11.4.4 インド 247
- 11.4.4.1 癌の早期診断に対する需要の高まりが市場成長を促進 247
11.4.5 オーストラリア 251
11.4.6 その他のアジア太平洋 255
11.5 ラテンアメリカ 258
11.5.1 ラテンアメリカ：リセッション時のインパクト 262
11.5.2 ブラジル 262
- 11.5.2.1 生活習慣病の増加が市場成長を促進 262
11.5.3 メキシコ 265
- 11.5.3.1 医療ツーリズムの増加でコンパニオン診断の需要が高まる 265
11.5.4 その他のラテンアメリカ 269
11.6 中東・アフリカ 272
11.6.1 精密医療への注目の高まりが市場成長を促進 272
11.6.2 中東・アフリカ：リセッション時のインパクト 275
11.7 GCC地域 276
11.7.1 成長する医療インフラが市場の成長を促進 276
11.7.2 GCC地域：リセッション時のインパクト 279
12 競合情勢 280
12.1 イントロダクション 280
12.2 主要プレーヤーが採用するRight-to-Winアプローチ 280
12.3 REVENUE SHARE ANALYSIS 282
12.4 市場シェア分析 282
12.5 企業評価マトリックス：主要企業 284
12.5.1 STARS 284
12.5.2 EMERGING LEADERS 284
12.5.3 PERVASIVE PLAYERS 284
12.5.4 PARTICIPANTS 285
12.5.5 企業フットプリント 286
- 12.5.5.1 全体のフットプリント 286
- 12.5.5.2 製品のフットプリント 286
- 12.5.5.3 テクノロジー・フットプリント 287
- 12.5.5.4 表示フットプリント 287
- 12.5.5.5 地域フットプリント 288
12.6 競争評価マトリックス：スタートアップ / 中小企業 288
12.6.1 PROGRESSIVE COMPANIES 288
12.6.2 RESPONSIVE COMPANIES 288
12.6.3 DYNAMIC COMPANIES 288
12.6.4 STARTING BLOCKS 289
12.6.5 競合ベンチマーキング 290
12.7 VALUATION AND FINANCIAL METRICS OF COMPANION DIAGNOSTICS VENDORS 291
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 292
12.8.1 F. HOFFMANN-LA ROCHE LTD 292
12.8.2 AGILENT TECHNOLOGIES, INC 292
12.8.3 QIAGEN 292
12.8.4 THERMO FISHER SCIENTIFIC INC 293
12.8.5 ABBOTT 293
12.9 競合シナリオ 293
12.9.1 製品ローンチ・承認 293
12.9.2 ディール 294
13 企業プロファイル 295
13.1 主要企業 295
13.1.1 F. HOFFMANN-LA ROCHE LTD 295
13.1.2 AGILENT TECHNOLOGIES, INC 302
13.1.3 QIAGEN 307
13.1.4 THERMO FISHER SCIENTIFIC INC 312
13.1.5 ABBOTT 318
13.1.6 DANAHER 322
13.1.7 GUARDANT HEALTH 325
13.1.8 ILLUMINA, INC 329
13.1.9 BIOMÉRIEUX 333
13.1.10 ICON PLC 335
13.1.11 MYRIAD GENETICS, INC 337
13.1.12 SYSMEX CORPORATION 340
13.2 他の有力企業 343
13.2.1 ALMAC GROUP 343
13.2.2 ARUP LABORATORIES 344
13.2.3 ABNOVA CORPORATION 345
13.2.4 BIOGENEX 346
13.2.5 INVIVOSCRIBE, INC 347
13.2.6 ARCHERDX, INC 348
13.2.7 Q² SOLUTIONS 349
13.2.8 AMOY DIAGNOSTICS CO., LTD 350
13.2.9 UNIOGEN 351
13.2.10 ASURAGEN, INC 352
13.2.11 MESO SCALE DIAGNOSTICS, LLC 353
13.2.12 CREATIVE BIOLABS 354
13.2.13 NG BIOTECH 355
14 付録 356
14.1 ディスカッションガイド 356
14.2 ナレッジストア 361
14.3 カスタマイズオプション 363
14.4 関連レポート 363
14.5 執筆者の詳細 364
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
Table of Contents
1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.2.1 INCLUSIONS & EXCLUSIONS 47
1.3 MARKET SEGMENTATION 48
1.3.1 MARKETS COVERED 48
1.3.2 REGIONS COVERED 49
1.3.3 YEARS CONSIDERED 49
1.4 CURRENCY CONSIDERED 50
1.5 RESEARCH LIMITATIONS 50
1.6 MARKET STAKEHOLDERS 50
1.7 SUMMARY OF CHANGES 51
1.7.1 RECESSION IMPACT 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH DATA 52
2.2 RESEARCH APPROACH 52
2.2.1 SECONDARY DATA 53
- 2.2.1.1 Key data from secondary sources 54
2.2.2 PRIMARY DATA 55
- 2.2.2.1 Primary sources 55
- 2.2.2.2 Key data from primary sources 56
- 2.2.2.3 Key industry insights 57
- 2.2.2.4 Breakdown of primary interviews 57
2.3 MARKET SIZE ESTIMATION 58
2.3.1 BOTTOM-UP APPROACH 59
- 2.3.1.1 Approach 1: Company revenue estimation approach 59
- 2.3.1.2 Approach 2: Presentations of companies and primary interviews 59
- 2.3.1.3 Growth forecast 60
- 2.3.1.4 CAGR projections 60
2.3.2 TOP-DOWN APPROACH 60
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 62
2.5 STUDY ASSUMPTIONS 63
2.6 GROWTH RATE ASSUMPTIONS 63
2.7 LIMITATIONS 63
2.8 RISK ASSESSMENT 64
2.8.1 RISK ASSESSMENT ANALYSIS 64
2.9 RECESSION IMPACT ANALYSIS 64
3 EXECUTIVE SUMMARY 66
4 PREMIUM INSIGHTS 71
4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW 71
4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2024 VS. 2029 71
4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029 72
4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2024 VS. 2029 72
4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY SAMPLE TYPE, 2024 VS. 2029 73
4.6 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029 73
4.7 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 74
5 MARKET OVERVIEW 75
5.1 INTRODUCTION 75
5.2 MARKET DYNAMICS 75
5.2.1 DRIVERS 76
- 5.2.1.1 Ability of CDx tests to reduce healthcare costs and increase efficiency 76
- 5.2.1.2 Growing focus on targeted therapy 76
- 5.2.1.3 Rising demand for personalized medicine 77
- 5.2.1.4 Increasing incidence of cancer and subsequent adoption of CDx-based oncology medicine 78
- 5.2.1.5 Growing application areas for companion diagnostics 79
5.2.2 RESTRAINTS 79
- 5.2.2.1 Significant capital investment and low cost-benefit ratio 79
- 5.2.2.2 High cost of companion diagnostic tests 80
- 5.2.2.3 Unfavorable reimbursements 80
- 5.2.2.4 High cost of immunotherapy treatment 81
5.2.3 OPPORTUNITIES 82
- 5.2.3.1 Increasing demand for next-generation sequencing 82
- 5.2.3.2 Growing significance of companion diagnostics in drug development 83
- 5.2.3.3 Advancements in genomics research and rising clinical trials 83
5.2.4 CHALLENGES 84
- 5.2.4.1 Shortage of healthcare professionals 84
- 5.2.4.2 Limited awareness in emerging markets 84
5.3 PRICING ANALYSIS 85
5.4 PATENT ANALYSIS 86
5.5 TRADE ANALYSIS 87
5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 87
5.6 VALUE CHAIN ANALYSIS 87
5.7 SUPPLY CHAIN ANALYSIS 89
5.8 ECOSYSTEM ANALYSIS 90
5.9 PORTER’S FIVE FORCES ANALYSIS 91
5.9.1 THREAT OF NEW ENTRANTS 91
5.9.2 THREAT OF SUBSTITUTES 91
5.9.3 BARGAINING POWER OF BUYERS 91
5.9.4 BARGAINING POWER OF SUPPLIERS 92
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 92
5.10 REGULATORY LANDSCAPE 92
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
5.10.2 NORTH AMERICA 94
- 5.10.2.1 US 94
- 5.10.2.2 Canada 94
5.10.3 EUROPE 94
5.10.4 ASIA PACIFIC 95
- 5.10.4.1 China 95
- 5.10.4.2 Japan 95
- 5.10.4.3 India 96
5.10.5 LATIN AMERICA 96
- 5.10.5.1 Brazil 96
- 5.10.5.2 Mexico 97
5.10.6 MIDDLE EAST 97
5.10.7 AFRICA 97
5.11 TECHNOLOGY ANALYSIS 97
5.11.1 KEY TECHNOLOGIES 98
- 5.11.1.1 Polymerase chain reaction (PCR) 98
- 5.11.1.2 Next-generation sequencing (NGS) 98
5.11.2 COMPLIMENTARY TECHNOLOGIES 98
- 5.11.2.1 In situ hybridization (ISH) 98
5.11.3 ADJACENT TECHNOLOGIES 98
- 5.11.3.1 Immunohistochemistry (IHC) 98
5.12 KEY CONFERENCES & EVENTS IN 2024-2025 99
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
5.13.1 REVENUE POCKETS FOR COMPANION DIAGNOSTICS MARKET 100
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 101
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
5.14.2 BUYING CRITERIA 102
5.15 INVESTMENT AND FUNDING SCENARIO 103
6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 104
6.1 INTRODUCTION 105
6.2 ASSAYS, KITS, AND REAGENTS 105
6.2.1 INCREASING VOLUME OF CDX TESTS IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS 105
6.3 INSTRUMENTS & SYSTEMS 109
6.3.1 LATEST ADVANCEMENTS IN NGS TECHNOLOGIES TO ENSURE MARKET GROWTH 109
6.4 SOFTWARE & SERVICES 112
6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH 112
7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 116
7.1 INTRODUCTION 117
7.2 POLYMERASE CHAIN REACTION 117
7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH 117
7.3 IN SITU HYBRIDIZATION 121
7.3.1 INCREASING DEMAND IN SMALL TUMOR DIAGNOSTICS TO DRIVE GROWTH 121
7.4 NEXT-GENERATION SEQUENCING 124
7.4.1 ADVANTAGES SUCH AS ACCURACY, SENSITIVITY, AND SPEED TO SUPPORT MARKET GROWTH 124
7.5 IMMUNOHISTOCHEMISTRY 128
7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH 128
7.6 OTHER TECHNOLOGIES 131
8 COMPANION DIAGNOSTICS MARKET, BY INDICATION 135
8.1 INTRODUCTION 136
8.2 CANCER 136
8.2.1 LUNG CANCER 139
- 8.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption 139
8.2.2 BREAST CANCER 143
- 8.2.2.1 Wide prevalence of breast cancer to boost market growth 143
8.2.3 BLOOD CANCER 146
- 8.2.3.1 Growing incidence of blood cancer to drive market 146
8.2.4 COLORECTAL CANCER 149
- 8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth 149
8.2.5 OTHER CANCERS 152
8.3 NEUROLOGICAL DISEASES 154
8.3.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS 154
8.4 CARDIOVASCULAR DISEASES 157
8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH 157
8.5 INFECTIOUS DISEASES 160
8.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL GROWTH 160
8.6 OTHER INDICATIONS 163
9 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE 166
9.1 INTRODUCTION 167
9.2 TISSUE SAMPLES 167
9.2.1 COMPREHENSIVE PROFILING AND HIGH SENSITIVITY TO DRIVE MARKET 167
9.3 BLOOD SAMPLES 170
9.3.1 LESS INVASIVE METHOD-KEY FACTOR DRIVING ADOPTION 170
9.4 OTHER SAMPLE TYPES 173
10 COMPANION DIAGNOSTICS MARKET, BY END USER 177
10.1 INTRODUCTION 178
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 178
10.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET 178
10.3 REFERENCE LABORATORIES 181
10.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH 181
10.4 CONTRACT RESEARCH ORGANIZATIONS 184
10.4.1 RISING DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS TO PROPEL GROWTH 184
10.5 OTHER END USERS 187
11 COMPANION DIAGNOSTICS MARKET, BY REGION 191
11.1 INTRODUCTION 192
11.2 NORTH AMERICA 192
11.2.1 NORTH AMERICA: RECESSION IMPACT 197
11.2.2 US 198
- 11.2.2.1 Increasing use of companion diagnostics for cancer treatment to boost market growth 198
11.2.3 CANADA 201
- 11.2.3.1 Increasing government initiatives to drive market 201
11.3 EUROPE 205
11.3.1 EUROPE: RECESSION IMPACT 209
11.3.2 GERMANY 210
- 11.3.2.1 Increasing healthcare expenditure to drive market 210
11.3.3 UK 213
- 11.3.3.1 Growing life science industry and increasing focus on research to propel market 213
11.3.4 SWITZERLAND 217
- 11.3.4.1 Strong research-oriented pharma industry to support market growth 217
11.3.5 FRANCE 220
- 11.3.5.1 Increasing government funding for research to support market growth 220
11.3.6 ITALY 224
- 11.3.6.1 Growing geriatric population in region to drive market 224
11.3.7 SPAIN 227
- 11.3.7.1 Increasing focus on advancement of personalized medicine to drive market growth 227
11.3.8 REST OF EUROPE 231
11.4 ASIA PACIFIC 235
11.4.1 ASIA PACIFIC: RECESSION IMPACT 240
11.4.2 CHINA 240
- 11.4.2.1 Advancements in healthcare facilities to drive market 240
11.4.3 JAPAN 244
- 11.4.3.1 Increasing research initiatives to support market growth 244
11.4.4 INDIA 247
- 11.4.4.1 Increased demand for early cancer diagnosis to fuel market growth 247
11.4.5 AUSTRALIA 251
- 11.4.5.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market 251
11.4.6 REST OF ASIA PACIFIC 255
11.5 LATIN AMERICA 258
11.5.1 LATIN AMERICA: RECESSION IMPACT 262
11.5.2 BRAZIL 262
- 11.5.2.1 Increasing incidence of lifestyle diseases to favor market growth 262
11.5.3 MEXICO 265
- 11.5.3.1 Growing medical tourism to fuel demand for companion diagnostics 265
11.5.4 REST OF LATIN AMERICA 269
11.6 MIDDLE EAST & AFRICA 272
11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH 272
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 275
11.7 GCC COUNTRIES 276
11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH 276
11.7.2 GCC COUNTRIES: RECESSION IMPACT 279
12 COMPETITIVE LANDSCAPE 280
12.1 INTRODUCTION 280
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 280
12.3 REVENUE SHARE ANALYSIS 282
12.4 MARKET SHARE ANALYSIS 282
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 284
12.5.1 STARS 284
12.5.2 EMERGING LEADERS 284
12.5.3 PERVASIVE PLAYERS 284
12.5.4 PARTICIPANTS 285
12.5.5 COMPANY FOOTPRINT 286
- 12.5.5.1 Overall footprint 286
- 12.5.5.2 Product footprint 286
- 12.5.5.3 Technology footprint 287
- 12.5.5.4 Indication footprint 287
- 12.5.5.5 Regional footprint 288
12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES 288
12.6.1 PROGRESSIVE COMPANIES 288
12.6.2 RESPONSIVE COMPANIES 288
12.6.3 DYNAMIC COMPANIES 288
12.6.4 STARTING BLOCKS 289
12.6.5 COMPETITIVE BENCHMARKING 290
12.7 VALUATION AND FINANCIAL METRICS OF COMPANION DIAGNOSTICS VENDORS 291
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 292
12.8.1 F. HOFFMANN-LA ROCHE LTD 292
12.8.2 AGILENT TECHNOLOGIES, INC 292
12.8.3 QIAGEN 292
12.8.4 THERMO FISHER SCIENTIFIC INC 293
12.8.5 ABBOTT 293
12.9 COMPETITIVE SCENARIO 293
12.9.1 PRODUCT LAUNCHES & APPROVALS 293
12.9.2 DEALS 294
13 COMPANY PROFILES 295
13.1 KEY PLAYERS 295
13.1.1 F. HOFFMANN-LA ROCHE LTD 295
13.1.2 AGILENT TECHNOLOGIES, INC 302
13.1.3 QIAGEN 307
13.1.4 THERMO FISHER SCIENTIFIC INC 312
13.1.5 ABBOTT 318
13.1.6 DANAHER 322
13.1.7 GUARDANT HEALTH 325
13.1.8 ILLUMINA, INC 329
13.1.9 BIOMÉRIEUX 333
13.1.10 ICON PLC 335
13.1.11 MYRIAD GENETICS, INC 337
13.1.12 SYSMEX CORPORATION 340
13.2 OTHER PLAYERS 343
13.2.1 ALMAC GROUP 343
13.2.2 ARUP LABORATORIES 344
13.2.3 ABNOVA CORPORATION 345
13.2.4 BIOGENEX 346
13.2.5 INVIVOSCRIBE, INC 347
13.2.6 ARCHERDX, INC 348
13.2.7 Q² SOLUTIONS 349
13.2.8 AMOY DIAGNOSTICS CO., LTD 350
13.2.9 UNIOGEN 351
13.2.10 ASURAGEN, INC 352
13.2.11 MESO SCALE DIAGNOSTICS, LLC 353
13.2.12 CREATIVE BIOLABS 354
13.2.13 NG BIOTECH 355
14 APPENDIX 356
14.1 DISCUSSION GUIDE 356
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 361
14.3 CUSTOMIZATION OPTIONS 363
14.4 RELATED REPORTS 363
14.5 AUTHOR DETAILS 364
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES FOR BOTH GENDERS (AGE: 0-85+), 2022 VS. 2045 TABLE 2 COMPANION DIAGNOSTICS MARKET: REIMBURSEMENT GUIDELINES ACROSS REGIONS TABLE 3 DEALS UNDERTAKEN FOR DEVELOPMENT OF NGS-BASED COMPANION DIAGNOSTIC TESTS TABLE 4 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS TABLE 5 INDICATIVE PRICING FOR COMPANION DIAGNOSTICS PRODUCTS TABLE 6 AVERAGE SELLING PRICE OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION TABLE 7 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION) TABLE 8 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION) TABLE 9 COMPANION DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM TABLE 10 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 15 EUROPE: CLASSIFICATION OF DEVICES TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS TABLE 17 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION DIAGNOSTICS PRODUCTS (%) TABLE 19 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS TABLE 20 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 21 ASSAYS & KITS: PRODUCTS OFFERED, BY COMPANY TABLE 22 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2022-2029 (USD MILLION) TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 25 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 26 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 27 INSTRUMENTS & SYSTEMS: PRODUCTS OFFERED, BY COMPANY TABLE 28 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY REGION, 2022-2029 (USD MILLION) TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 32 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 33 SOFTWARE & SERVICES: PRODUCTS OFFERED, BY COMPANY TABLE 34 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022-2029 (USD MILLION) TABLE 35 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION TABLE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 39 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 40 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION TABLE 41 MAJOR PCR TESTS/KITS AVAILABLE TABLE 42 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2029 (USD MILLION) TABLE 43 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 44 EUROPE: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 45 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 46 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 47 MAJOR ISH TESTS/KITS AVAILABLE TABLE 48 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022-2029 (USD MILLION) TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 50 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 51 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 53 MAJOR NGS TESTS/KITS AVAILABLE TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022-2029 (USD MILLION) TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 59 MAJOR IHC TESTS/KITS AVAILABLE TABLE 60 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022-2029 (USD MILLION) TABLE 61 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 63 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 64 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 65 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION) TABLE 66 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 68 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 69 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 70 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 71 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040 TABLE 72 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 73 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION) TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 75 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 76 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 77 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 78 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040 TABLE 79 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022-2029 (USD MILLION) TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 81 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 82 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 83 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 84 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040 TABLE 85 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022-2029 (USD MILLION) TABLE 86 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 87 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 88 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 89 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 90 ESTIMATED NUMBER OF LEUKEMIA CASES, BY REGION, 2022 VS. 2040 TABLE 91 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY REGION, 2022-2029 (USD MILLION) TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 96 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040 TABLE 97 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2029 (USD MILLION) TABLE 98 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 99 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 100 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 101 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 102 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2022-2029 (USD MILLION) TABLE 103 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 105 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 106 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 107 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022-2029 (USD MILLION) TABLE 108 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 110 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 111 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION) TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 117 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION) TABLE 118 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 119 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 120 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 121 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 122 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION) TABLE 123 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 124 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 125 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 126 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 127 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 128 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTIC PRODUCTS TABLE 129 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2022-2029 (USD MILLION) TABLE 130 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 131 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 132 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 133 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 134 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTIC PRODUCTS TABLE 135 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION) TABLE 136 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 137 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 138 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 139 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 140 EXAMPLES OF OTHER SAMPLE-BASED COMPANION DIAGNOSTIC PRODUCTS TABLE 141 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022-2029 (USD MILLION) TABLE 142 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 143 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 144 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 146 COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 147 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION) TABLE 148 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 149 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 150 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 151 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 152 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION) TABLE 153 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 154 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 155 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 156 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 157 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION) TABLE 158 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 159 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 160 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 161 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 162 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION) TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 167 COMPANION DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION) TABLE 168 NUMBER OF NEW CANCER CASES IN NORTH AMERICA, BY TYPE OF CANCER, 2022 VS. 2045 TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 170 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 171 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 172 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 173 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 174 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 176 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 TABLE 177 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 178 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 179 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 180 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 181 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 182 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 183 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 TABLE 184 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 185 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 186 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 187 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 188 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 189 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 191 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 192 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 193 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 194 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 195 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 196 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 197 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 198 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 199 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 200 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 201 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 202 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 203 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 204 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 205 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 206 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 207 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 208 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 209 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 210 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 211 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 212 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 213 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 214 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 215 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 216 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 217 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 218 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 219 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 220 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 221 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 222 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 223 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 224 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 225 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 226 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 227 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 228 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 229 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 230 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 231 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 232 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 233 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 234 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 235 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 236 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 237 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 238 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 239 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 240 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 241 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 242 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 243 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 244 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 245 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 246 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 TABLE 247 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 248 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 249 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 250 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 251 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 252 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 253 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 TABLE 254 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 255 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 256 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 257 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 258 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 259 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 260 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 TABLE 261 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 262 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 263 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 264 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 265 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 266 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 267 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 268 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 269 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 270 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 271 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 272 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 273 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 274 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 275 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 276 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 277 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 278 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 279 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION) TABLE 280 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 281 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 282 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 283 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 284 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 285 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 286 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 287 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 288 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 289 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 290 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 291 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 292 MEXICO: NEW CANCER CASES, 2022 TABLE 293 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 294 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 295 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 296 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 297 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 298 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 299 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 300 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 301 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 302 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 303 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 304 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 306 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 307 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 308 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 309 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 310 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 311 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION) TABLE 312 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) TABLE 313 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION) TABLE 314 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION) TABLE 315 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION) TABLE 316 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION) TABLE 317 COMPANION DIAGNOSTICS MARKET: STRATEGIES ADOPTED TABLE 318 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION TABLE 319 COMPANION DIAGNOSTICS MARKET: PRODUCT FOOTPRINT TABLE 320 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT TABLE 321 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT TABLE 322 COMPANION DIAGNOSTICS MARKET: REGIONAL FOOTPRINT TABLE 323 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES TABLE 324 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES TABLE 325 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024 TABLE 326 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2021-MARCH 2024 TABLE 327 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW TABLE 328 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 329 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS TABLE 330 F. HOFFMANN-LA ROCHE LTD.: DEALS TABLE 331 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW TABLE 332 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 333 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS TABLE 334 AGILENT TECHNOLOGIES, INC.: DEALS TABLE 335 QIAGEN: COMPANY OVERVIEW TABLE 336 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 337 QIAGEN: PRODUCT LAUNCHES & APPROVALS TABLE 338 QIAGEN: DEALS TABLE 339 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW TABLE 340 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 341 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS TABLE 342 THERMO FISHER SCIENTIFIC INC.: DEALS TABLE 343 ABBOTT: COMPANY OVERVIEW TABLE 344 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 345 DANAHER: COMPANY OVERVIEW TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 347 GUARDANT HEALTH: COMPANY OVERVIEW TABLE 348 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 349 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS TABLE 350 GUARDANT HEALTH: DEALS TABLE 351 GUARDANT HEALTH: OTHER DEVELOPMENTS TABLE 352 ILLUMINA, INC.: COMPANY OVERVIEW TABLE 353 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 354 ILLUMINA, INC.: PRODUCT LAUNCHES TABLE 355 ILLUMINA, INC.: DEALS TABLE 356 BIOMÉRIEUX: COMPANY OVERVIEW TABLE 357 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 358 ICON PLC: COMPANY OVERVIEW TABLE 359 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 360 MYRIAD GENETICS, INC.: COMPANY OVERVIEW TABLE 361 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 362 MYRIAD GENETICS, INC.: PRODUCT APPROVALS TABLE 363 MYRIAD GENETICS, INC.: DEALS TABLE 364 SYSMEX CORPORATION: COMPANY OVERVIEW TABLE 365 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED TABLE 366 SYSMEX CORPORATION: DEALS TABLE 367 SYSMEX CORPORATION: OTHER DEVELOPMENTS TABLE 368 ALMAC GROUP: COMPANY OVERVIEW TABLE 369 ARUP LABORATORIES: COMPANY OVERVIEW TABLE 370 ABNOVA CORPORATION: COMPANY OVERVIEW TABLE 371 BIOGENEX: COMPANY OVERVIEW TABLE 372 INVIVOSCRIBE, INC.: COMPANY OVERVIEW TABLE 373 ARCHERDX, INC.: COMPANY OVERVIEW TABLE 374 Q² SOLUTIONS: COMPANY OVERVIEW TABLE 375 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW TABLE 376 UNIOGEN: COMPANY OVERVIEW TABLE 377 ASURAGEN, INC.: COMPANY OVERVIEW TABLE 378 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW TABLE 379 CREATIVE BIOLABS: COMPANY OVERVIEW TABLE 380 NG BIOTECH: COMPANY OVERVIEW
FIGURE 1 RESEARCH DESIGN METHODOLOGY FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH FIGURE 7 DATA TRIANGULATION METHODOLOGY FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION) FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) FIGURE 14 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH FIGURE 15 ASSAYS, KITS, AND REAGENTS TO DOMINATE MARKET IN 2029 FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD FIGURE 17 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD FIGURE 18 TISSUE SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2029 FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 22 PERSONALIZED MEDICINE APPROVALS BY US FDA (2015-2022) FIGURE 23 GLOBAL CANCER INCIDENCE (2008-2030) FIGURE 24 PATENT ANALYSIS OF COMPANION DIAGNOSTICS SYSTEMS (JANUARY 2014-DECEMBER 2023) FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES FIGURE 26 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS FIGURE 27 ECOSYSTEM MAP FIGURE 28 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPANION DIAGNOSTICS PRODUCTS FIGURE 30 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS FIGURE 31 COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO FIGURE 32 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT FIGURE 33 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS (2019-2023) FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) FIGURE 36 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 FIGURE 37 COMPANION DIAGNOSTICS MARKET: OVERALL FOOTPRINT FIGURE 38 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 FIGURE 39 EV/EBITDA OF KEY VENDORS FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FIGURE 41 PRODUCT/BRAND COMPARATIVE ANALYSIS, BY PARAMETER FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2023) FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2023) FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023) FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2023) FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) FIGURE 51 ICON PLC: COMPANY SNAPSHOT (2023) FIGURE 52 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023) FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
